Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen
Phase 2CompletedDevelopment Stage
Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Feb 8, 2019 → Oct 13, 2022
About Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen
Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen is a phase 2 stage product being developed by Pfizer for Anatomic Stage IV Breast Cancer AJCC v8. The current trial status is completed. This product is registered under clinical trial identifier NCT03691493. Target conditions include Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03691493 | Phase 2 | Completed |
Competing Products
13 competing products in Anatomic Stage IV Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 33 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 22 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 49 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 25 |
| Neratinib | Puma Biotechnology | Phase 2 | 44 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |